Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ramsey Baghdadi

Ramsey Baghdadi covered regulation, reimbursement, and legislative policy for over a decade as Editor-in-Chief of The RPM Report and a contributing editor to Pink Sheet. He previously served as managing editor for the OTC drug and dietary supplement industry publication The Tan Sheet. Prior to his work in the drug sector, he covered the medical device industry as financial editor of The Gray Sheet.

Latest From Ramsey Baghdadi

COVID-19 And The Future Of Rx Pricing Policy: An Interview With White House Advisor Grogan

White House Domestic Policy Council Director Joe Grogan is departing at the end of May. In an interview, he talked about lessons (so far) from the COVID-19 response and the future of drug pricing policy against the backdrop of the pandemic.

Pricing Debate Coronavirus COVID-19

Medicare-For-Hmmm: A Year Of House Hearings Show Democratic Disunity

Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.

Medicare Pricing Debate

US FDA's New Neurology Leadership Likely To Face Two Big Reviews In 2020

Eric Bastings will lead Division of Neurology I, which is expected to handle Biogen’s Alzheimer’s drug aducanumab and Sarepta’s refiling of golodirsen for DMD next year.

Neurology Drug Approval Standards

For Biopharma, There May Be Only One Race To Watch In 2020

Senate Majority Leader McConnell is the one constant keeping drug price controls from gaining any legislative traction.

Pricing Debate Legislation

A Short Eulogy For The Rebate Rule

The rebate rule is dead, but we should pay tribute to the failed endeavor.

Pricing Debate Medicare

Drug Price Transparency Bills May Be Empty Calories

Price justification legislation is advancing in both chambers of Congress. But CBO scores them as no savings. 

Pricing Debate Legislation
See All
UsernamePublicRestriction

Register